A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas

Creemers, Aafke; Ebbing, Eva A.; Pelgrim, Thomas; Lagarde, Sjoerd M.; Etten-Jamaludin, Faridi S. van; Henegouwen, Mark I. van Berge; Hulshof, Maarten C.C.M.; Krishnadath, Kausilia K.; Meijer, Sybren L.; Bijlsma, Maarten F.; Oijen, Martijn G.H. van; Laarhoven, Hanneke W. M. van

doi:10.1038/s41598-018-31548-6

Cited by 30 publications

(20 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, they noticed that patients with OSA had a moderately shorter time interval between conclusion of radiation and sleep study date, advising that more immediate post-radiation changes (oedema) may make a patient more susceptible to developing OSA than the later post-radiation changes (fibrosis) [27]. Furthermore, the oedema may be worsened by hypothyroidism following radiation therapy [40]. Lastly, damage to the salivary glands can lead to a lack of saliva, reducing lubrication of the oral and oropharyngeal mucosa, thereby increasing upper airway resistance [41].…”

Section: Discussionmentioning

confidence: 99%

Obstructive Sleep Apnoea in Patients Treated for Head and Neck Cancer: A Systematic Review of the Literature

et al. 2020

View full text Add to dashboard Cite

Background and objectives: Obstructive sleep apnoea (OSA) is clinically defined by signs of daytime sleepiness and objective measures of disordered breathing during sleep. The literature is still controversial on the incidence and aetiology of OSA secondary to head and neck cancer treatment. The aim of this systematic review is to evaluate and discuss the prevalence of OSA in patients treated with surgery and/or chemo/radiotherapy for head and neck cancer. Materials and methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search was performed on May 2020 using the MEDLINE database, Scopus, and Google Scholar. The searches were conducted using combinations of the following terms: head and neck cancer, OSA, radiotherapy, chemotherapy, partial laryngectomy, laryngeal cancer, neoplasm, tumour, carcinoma, and oropharyngeal cancer. Results: Our results suggest that head and neck cancer patients have a higher incidence of OSA (59.78%) compared to the general population; differences may occur based on the type of treatment. Conclusions: Clinicians should recognise the higher prevalence of OSA in patients treated for head and neck cancer and should consider a comprehensive sleep history as part of the evaluation and management of these patients. Further research is needed to evaluate the exact prevalence, aetiology, and correct management of OSA after treatment for head and neck cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Obstructive Sleep Apnoea in Patients Treated for Head and Neck Cancer: A Systematic Review of the Literature

et al. 2020

View full text Add to dashboard Cite

show abstract

“…64 c-Met is overexpressed in EAC, which is related to the poor prognosis in EAC treatment. 65 Yan et al demonstrated that the protein expression of c-Met was higher in EC tissues than in adjacent tissues, and high c-Met expression was related to clinical stage, depth of invasion, and lymph node metastasis. 66 Therefore, quite a few drugs targeting the c-Met/HGF pathway are also in development and function by either preventing the binding of HGF and c-Met or directly targeting c-Met to subsequently inhibit the c-Met/HGF signaling pathway.…”

Section: Targeting Key Signaling Pathwaysmentioning

confidence: 99%

Advances in targeted therapy for esophageal cancer

Yang

Pan

Xu³

et al. 2020

Sig Transduct Target Ther

298

246

View full text Add to dashboard Cite

Esophageal cancer (EC) is one of the most lethal cancers in the world, and its morbidity and mortality rates rank among the top ten in China. Currently, surgical resection, radiotherapy and chemotherapy are the primary clinical treatments for esophageal cancer. However, outcomes are still unsatisfactory due to the limited efficacy and severe adverse effects of conventional treatments. As a new type of approach, targeted therapies have been confirmed to play an important role in the treatment of esophageal cancer; these include cetuximab and bevacizumab, which target epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), respectively. In addition, other drugs targeting surface antigens and signaling pathways or acting on immune checkpoints have been continuously developed. For example, trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER-2), has been approved by the Food and Drug Administration (FDA) as a first-line treatment of HER-2-positive cancer. Moreover, the PD-L1 inhibitor pembrolizumab has been approved as a highly efficient drug for patients with PD-L1-positive or advanced esophageal squamous cell carcinoma (ESCC). These novel drugs can be used alone or in combination with other treatment strategies to further improve the treatment efficacy and prognosis of cancer patients. Nevertheless, adverse events, optimal dosages and effective combinations still need further investigation. In this review, we expound an outline of the latest advances in targeted therapies of esophageal cancer and the mechanisms of relevant drugs, discuss their efficacy and safety, and provide a clinical rationale for precision medicine in esophageal cancer.

show abstract

“…Aberrant MET activation plays a critical role in tumor cell proliferation, invasion, and angiogenesis [ 89 ]. Genomic amplification of MET has been demonstrated to be a poor prognostic indicator in EAC [ 90 , 91 ].…”

Section: Targeted Therapiesmentioning

confidence: 99%

Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?

Khalafi

Lockhart

Livingstone

et al. 2020

Cancers

View full text Add to dashboard Cite

Esophageal adenocarcinoma is one of the leading causes of cancer-related deaths worldwide. The incidence of esophageal adenocarcinoma has increased at an alarming rate in the Western world and long-term survival remains poor. Current treatment approaches involve a combination of surgery, chemotherapy, and radiotherapy. Unfortunately, standard first-line approaches are met with high rates of recurrence and metastasis. More recent investigations into the distinct molecular composition of these tumors have uncovered key genetic and epigenetic alterations involved in tumorigenesis and progression. These discoveries have driven the development of targeted therapeutic agents in esophageal adenocarcinoma. While many agents have been studied, therapeutics targeting the human epidermal growth factor receptor (HER2) and vascular endothelial growth factor (VEGF) pathways have demonstrated improved survival. More recent advances in immunotherapies have also demonstrated survival advantages with monoclonal antibodies targeting the programmed death ligand 1 (PD-L1). In this review we highlight recent advances of targeted therapies, specifically agents targeting receptor tyrosine kinases, small molecule kinase inhibitors, and immune checkpoint inhibitors. While targeted therapeutics and immunotherapies have significantly improved survival, the benefits are limited to patients whose tumors express biomarkers such as PD-L1 and HER2. Survival remains poor for the remainder of patients with esophageal adenocarcinoma, underscoring the critical need for development of novel treatment strategies.

show abstract

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas

Cited by 30 publications

References 103 publications

Obstructive Sleep Apnoea in Patients Treated for Head and Neck Cancer: A Systematic Review of the Literature

Obstructive Sleep Apnoea in Patients Treated for Head and Neck Cancer: A Systematic Review of the Literature

Advances in targeted therapy for esophageal cancer

Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?

Contact Info

Product

Resources

About